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It is not known how influenza A viruses, important human pathogens, counter PKR activation, a crucial host antiviral response. Here we
elucidate this mechanism. We show that the direct binding of PKR to the NS1 protein in vitro that results in inhibition of PKR activation requires
the NS1 123–127 amino acid sequence. To establish whether such direct binding of PKR to the NS1 protein is responsible for inhibiting PKR
activation in infected cells, we generated recombinant influenza A/Udorn/72 viruses expressing NS1 proteins in which amino acids 123/124 or
126/127 are changed to alanines. In cells infected with these mutant viruses, PKR is activated, eIF-2α is phosphorylated and viral protein synthesis
is inhibited, indicating that direct binding of PKR to the 123–127 sequence of the NS1 protein is necessary and sufficient to block PKR activation
in influenza A virus-infected cells. Unexpectedly, the 123/124 mutant virus is not attenuated because reduced viral protein synthesis is offset by
enhanced viral RNA synthesis at very early times of infection. These early viral RNAs include those synthesized predominantly at later times
during wild-type virus infection, demonstrating that wild-type temporal regulation of viral RNA synthesis is absent in 123/124 virus-infected cells.
Enhanced early viral RNA synthesis after 123/124 virus infection also occurs in mouse PKR−/− cells, demonstrating that PKR activation and
deregulation of the time course of viral RNA synthesis are not coupled. These results indicate that the 123/124 site of the NS1A protein most
likely functionally interacts with the viral polymerase to mediate temporal regulation of viral RNA synthesis. This interaction would occur in the
nucleus, whereas PKR would bind to NS1A proteins in the cytoplasm prior to their import into the nucleus.
© 2007 Elsevier Inc. All rights reserved.Keywords: Influenza A virus; NS1 protein; PKR activation; Viral RNA synthesisIntroduction
The protein kinase PKR is constitutively expressed in
mammalian cells and is further increased by interferon (IFN)
treatment (Hovanessian, 1989; Meurs et al., 1990). After
activation by binding either double-stranded RNA (dsRNA) or
the cellular PACT protein (Galabru and Hovanessian, 1987;
Patel and Sen, 1998), PKR phosphorylates the α subunit of the
eIF2 translation initiation factor, resulting in the inhibition of
cellular and viral protein synthesis and viral replication (Gale
and Katze, 1998; Samuel, 1993). Hence, PKR is a major
component of the cellular antiviral system, and it is crucial for⁎ Corresponding author. Fax: +1 512 232 5565.
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doi:10.1016/j.virol.2007.01.038viruses to block PKR activation or the downstream effects
resulting from its activation.
Many viruses use different strategies to inhibit the antiviral
actions of PKR (Gale and Katze, 1998). Here we focus on the
strategy employed by influenza A viruses, which are important
human pathogens that are responsible for seasonal epidemics as
well as for periodic pandemics that result in high mortality rates
(Wright and Webster, 2001). PKR is not activated after infection
by influenza A virus (Katze et al., 1986), but the mechanism by
which the virus inhibits PKR activation has not been
established. Two mechanisms that have been postulated involve
the viral NS1 protein (NS1A protein), a multi-functional protein
that participates in both protein–RNA and protein–protein
interactions. The N-terminal 73-amino acid RNA-binding
domain of the NS1A protein specifically binds A-form
dsRNA, albeit with low affinity (Chien et al., 2004; Hatada
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1996b). The rest of the NS1A protein, which is denoted as the
effector domain, has binding sites for several cellular proteins. It
binds the 30-kDa subunit of the cellular cleavage and
polyadenylation specificity factor (CPSF30), resulting in the
inhibition of the 3′ end processing of cellular pre-mRNAs (Li et
al., 2001; Nemeroff et al., 1998; Noah et al., 2003; Twu et al.,
2006), and also binds p85β, resulting in the activation of
phosphatidylinositol-3-kinase (PI13K) signaling (Hale et al.,
2006). It has been proposed that: (i) the N-terminal RNA-
binding domain of the NS1A protein sequesters dsRNA away
from PKR (Garcia-Sastre, 2001; Hatada et al., 1999; Lu et al.,
1995); or (ii) inhibition of PKR activation results from the direct
binding of PKR to the NS1A protein (Li et al., 2006a). In
addition, it has been proposed that a cellular protein is involved
in inhibiting PKR activation, specifically that influenza A virus
infection activates a cellular PKR inhibitor, p58IPK (Melville et
al., 1999). It was possible that both the viral NS1A protein and
the cellular p58IPK protein participate in the inhibition of PKR
activation in infected cells.
The role of the dsRNA-binding activity of the NS1A protein
in inhibiting PKR activation has been assessed using a
recombinant influenza A/Udorn/72 virus expressing a NS1A
protein lacking only dsRNA-binding activity (Min and Krug,
2006). PKR is not activated in cells infected by this mutant
virus, indicating that sequestering of dsRNA by the NS1A
protein is not required for the inhibition of PKR activation in
infected cells. However, this result did not eliminate the
possibility that activated cellular p58IPK protein by itself can
block PKR activation in the absence of NS1A-mediated dsRNA
binding. In vitro binding assays provided support for the role of
direct binding of the NS1A protein to PKR in the inhibition of
PKR activation (Li et al., 2006a). Direct binding of the NS1A
protein in vitro to the N-terminal 230-amino acid region of PKR
inhibited PKR activation, and both PKR binding and the
inhibition of its activation did not require the dsRNA-binding
activity of the NS1A protein. It is not known whether such
direct binding is responsible for the inhibition of PKR binding
in influenza A virus-infected cells, particularly as co-immuno-
precipitation experiments to identify NS1A–PKR complexes
have given conflicting results (Falcon et al., 1999; Tan and
Katze, 1998).
In the present study we use a genetic approach to elucidate
the mechanism by which PKR activation is inhibited in cells
infected by influenza A virus. Using recombinant influenza A/
Udorn/72 viruses with mutations in the NS gene, we demons-
trate that binding of PKR to a specific site in the NS1A protein,
its 123–127 amino acid sequence, is necessary and sufficient for
the inhibition of PKR activation in virus-infected cells. These
experiments also yielded an unanticipated insight into the
mechanism of another important feature of influenza A virus
infection, the temporal regulation of viral RNA synthesis.
Previous experiments have established that the transcription and
replication of viral genes in influenza A virus-infected cells is
divided into an early and a late phase (Krug et al., 1989; Shapiro
et al., 1987; Skehel, 1973), but the mechanism of this temporal
regulation has remained a mystery for approximately 20 years.We show that changes in amino acids 123 and 124 of the NS1A
protein result in the deregulation of the time course of viral
RNA synthesis, leading to the enhanced synthesis of most, if not
all, viral RNAs at very early times of infection. Further, we
show that this deregulation is independent of PKR activation,
indicating that the 123/124 amino acid site of the NS1A protein
most likely functionally interacts with the viral polymerase to
mediate temporal regulation of viral RNA synthesis.Results
Identification of the binding site for PKR on the NS1A protein
in vitro
We showed previously that direct binding of the influenza A
virus NS1 protein (NS1A protein) in vitro to the N-terminal
230-amino acid region of PKR inhibits PKR activation (Li et
al., 2006a). We employed these in vitro assays to identify the
specific binding site for PKR on the NS1A protein. In the first
set of mapping experiments, we used NS1A proteins containing
C-terminal truncations of various lengths (Fig. 1A). The N-
terminal region that contains only the dsRNA-binding domain,
the N-terminal 1–73 amino acid fragment (Wang and Krug,
1996a, 1996b), does not bind PKR nor inhibit its activation,
verifying that the dsRNA-binding activity of the NS1A protein
is not sufficient to inhibit PKR activation. The PKR activation
assay showed that the 73–150 amino acid region of NS1A is
required, and the PKR binding assay showed that the required
region is shorter, amino acids 125–150. Based on these results,
we generated a series of mutant NS1A proteins in which various
pairs of amino acids were replaced with two other amino acids,
usually two alanines. Fig. 1B shows the mutant NS1A proteins
that identified the PKR binding site. The mutant NS1A protein
containing alanines at positions 123 and 124 (123/124 mutant)
or at positions 126 and 127 (126/127 mutant) do not bind PKR,
indicating that amino acids 123–127 of the NS1A protein are
required for PKR binding in vitro.
The PKR binding site on the NS1A protein is required for the
inhibition of PKR activation in virus-infected cells
To establish whether direct binding of PKR to the NS1
protein is responsible for inhibiting PKR activation in infected
cells, we generated recombinant influenza A/Udorn/72 viruses
that encode NS1A proteins with either the 123/124 or the 126/
127 mutation, or as a control, the 120/121 mutation shown in
Fig. 1. It should be emphasized that the bases that were mutated
to produce these amino acid changes are in the intron that is
removed by splicing to produce NS2 mRNA and hence do not
change the amino acid sequence of the NS2 protein (Lamb and
Krug, 2001). Human A549 cells were infected at a high
multiplicity (5 plaque-forming units (pfu)/cell) with these
mutant Udorn viruses or with wild-type (wt) Udorn virus.
Mock-infected cells served as an additional control. Six
hours after infection or mock-infection, cell extracts were
analyzed by immunoblots using antibody specific for PKR that
Fig. 1. Binding of PKR to the NS1A protein in vitro that results in inhibition of PKR activation requires the NS1A 123–127 amino acid sequence. (A) Top: The effect
of GST-NS1A proteins containing the indicated N-terminal sequences on PKR activation in vitro. Bottom: The binding of FLAG-tagged PKR to GST-NS1A proteins
containing the indicated N-terminal sequences. (B) The binding of FLAG-tagged PKR to GST-NS1A proteins with the indicated amino acid substitutions.
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(Fig. 2A). PKR was activated in cells infected with either the
123/124 or the 126/127 mutant virus, but not in cells infected
with the wt or 120/121 mutant virus. Hence, mutation of the
NS1A amino acids (123–127) that constitute its PKR binding
site results in the activation of PKR during infection. We
conclude that the binding of PKR to this NS1A site is necessary
and sufficient for the inhibition of PKR activation in influenza
A virus-infected cells.
PKR activation in the mutant virus-infected cells results in
predicted downstream effects. Immunoblot analysis demon-
strated that eIF2-α is phosphorylated at serine 51 in cells
infected with either the 123/124 or 126/127 mutant virus (Fig.
2A). To determine the effect of PKR activation on viral protein
synthesis, cells infected with the 123/124 mutant virus were
labeled with (35S)-methionine and cysteine for 30 min at 4, 6
and 8 h post-infection (Fig. 2B). The rate of viral protein
synthesis dramatically decreases after 4 h post-infection, which
is not the case in cells infected with wt virus (see below). There
was only a slight decrease in the amount of two representative
viral mRNAs (M1 and HA mRNAs) after 4 h post-infection, as
measured by quantitative RT-PCR (Fig. 2C), indicating that the
dramatic decrease in viral protein synthesis after 4 h is not
caused by a reduction in viral mRNAs, but rather is at the level
of translation. As shown below, the inhibition of translation is
due solely to PKR activation.
Mutation of NS1A amino acids 123 and 124 results in a second
phenotype, the deregulation of the temporal regulation of viral
RNA synthesis
Unexpectedly, despite the dramatic decrease in the rate of
viral protein synthesis after 4 h of infection, the 123/124 virusis not attenuated (Fig. 3). The plaques formed by wild-type
and 123/124 mutant virus are similar in size, and during
multiple cycle growth, i. e., after infection with 0.001 pfu/
cell, the 123/124 virus actually replicated slightly faster than
the wt virus.
We identified the basis for the lack of attenuation of the
123/124 mutant virus: the 123/124 mutation also adversely
affects a previously undocumented function of the NS1A
protein, the temporal regulation of viral RNA synthesis. The
first evidence for this conclusion came from the difference in
the time course of viral protein synthesis in 123/124 mutant
virus-infected cells compared to that in wt virus-infected cells
(Fig. 4A). The rate of viral protein synthesis at 4 h post-
infection was approximately 10-times greater in 123/124 virus-
infected cells than in wt virus-infected cells. All viral proteins
identifiable by gel electrophoresis were synthesized at high
levels at 4 h in 123/124 virus-infected cells. Subsequent to 4 h
post-infection, viral protein synthesis in 123/124 virus-infected
cells decreased due to PKR activation. In contrast, in wt virus-
infected cells the rate of viral protein synthesis gradually
increased from 4 to 8 h post-infection, but did not achieve the
high rate of viral protein synthesis observed in 123/124 virus-
infected cells at 4 h.
As shown in Fig. 4B, the enhanced rate of viral protein
synthesis at 4 h after infection with the 123/124 mutant virus is
coupled with enhanced synthesis of viral mRNAs and virion
RNAs (vRNAs) at times prior to 4 h post-infection. As early as
0.75 h post-infection, the amounts of the M1, HA and NP
mRNAs in 123/124 virus-infected cells were significantly
higher than those in wt virus-infected cells. From 0.75 to 2 h
post-infection the levels of viral mRNAs and vRNAs in 123/124
virus-infected cells increased to approximately 4–6 fold the
levels in wt virus-infected cells, and at 3 h was 3–5-fold higher.
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present in 123/124- and wt virus-infected cells because virus-
specific RNA synthesis increased at these later times in wt
virus-infected cells. The enhanced synthesis of the M and HA
vRNAs, and their encoded viral mRNAs and proteins, M1 and
HA, at very early times in 123/124 virus-infected cells indicates
that the early-to-late switch in viral gene expression that occurs
in wt virus-infected cells (Krug et al., 1989; Shapiro et al., 1987;
Skehel, 1973) no longer operates in the 123/124 mutant virus-
infected cells. In wt virus-infected cells the synthesis of M1 and
HA, which are major structural proteins, are synthesized
predominately at later times after infection as a result of a
later onset in the synthesis of their vRNAs and mRNAs (Krug et
al., 1989; Shapiro et al., 1987). In contrast, both early and late
vRNAs, viral mRNAs and proteins are synthesized at early
times in 123/124 virus-infected cells.Fig. 3. The 123/124 mutant virus is not attenuated. (A) Plaque sizes of the wt and
123/124 mutant virus. (B) Multiple cycle growth curves of the wt and 123/124
mutant virus.
Fig. 2. PKR is activated in cells infected by recombinant influenza A/Udorn/72
viruses expressing NS1A proteins in which amino acids 123/124 or 126/127 are
changed to alanines. (A) At 6 h after mock infection or infection with the wt or
indicated mutant virus, cell extracts were analyzed by immunoblots using
antibody specific for either phosphorylated PKR, total PKR, phosphorylated
eIF2α, or tubulin (gel loading control). Antibodies specific for PKR phos-
phorylated at threonine 445 and for eIF2α phosphorylated at serine 51 were
purchased from Cell Signaling. (B) The rate of viral protein synthesis at the
indicated times after infection with the 123/124 mutant virus. 35S-labeled
proteins were resolved by SDS-polyacrylamide gel electrophoresis. (C) The
relative amounts of the M1 and HA viral mRNAs at 4, 6 and 8 h after infection
with the 123/124 mutant virus.Deregulation of temporal regulation of viral RNA synthesis
also occurs in mouse PKR knockout cells infected with the
123/124 mutant virus
To determine whether PKR activation and the deregulation
of the time course of viral RNA synthesis are coupled, we used
mouse cells lacking PKR (Yang et al., 1995). In mouse PKR−/−
cells, inhibition of viral protein synthesis no longer occurs in
cells infected with the 123/124 mutant virus (Fig. 5A, compare
lanes 15 and 16 to lanes 8 and 9), verifying that protein
synthesis inhibition in 123/124 virus-infected cells is caused
solely by PKR activation. In addition, in PKR−/− cells the
synthesis of viral proteins, including late proteins, occurs at a
substantially greater rate in 123/124 virus-infected cells than in
wt virus-infected cells (compare lanes 14–16 to lanes 11–13).
For example, viral protein synthesis, including the synthesis of
the late M1 protein, is readily detected at 2 h after infection in
123/124 virus-infected cells, whereas viral protein synthesis is
barely detectable at 2 h in wt virus-infected cells. Enhanced
viral protein synthesis in 123/124 virus-infected PKR−/− cells
is coupled to enhanced viral mRNA synthesis at early times
after infection: the amounts of the M1 and NP mRNAs in 123/
124 virus-infected cells at 2 h post-infection were 5–6 times
higher than in wt virus-infected cells (Fig. 5B). These results
demonstrate that the two phenotypes resulting from the 123/124
mutation in the NS1A protein, PKR activation and deregulation
of the time course of viral RNA synthesis, are not coupled.
Discussion
In this study we use a genetic approach to elucidate the
mechanism by which PKR activation is inhibited in influenza A
Fig. 4. The wt temporal regulation of viral RNA synthesis is absent in cells infected by the 123/124 mutant virus. (A) Comparison of the rate of viral protein synthesis
at the indicated times after 123/124 virus infection with the rate at these time points after wt virus infection. The results of lanes 2–4 of Fig. 2B are reshown here in
lanes 5–7. (B) Left: The amounts of the viral HA, M1 and NP mRNAs during the first 4 h after 123/124 virus infection relative to the amounts of these mRNAs during
this time period after wt virus infection. Right: The amounts of the HA, M and NP vRNAs during the first 4 h after 123/124 virus infection relative to the amounts of
these vRNAs during this time period after wt virus infection. M vRNA encodes both the M1 and M2 viral proteins.
240 J.-Y. Min et al. / Virology 363 (2007) 236–243virus-infected cells. We show that direct binding of PKR to the
NS1A protein in vitro that results in inhibition of PKR
activation requires the NS1A 123–127 amino acid sequence,
and that PKR is activated in cells infected with a recombinant
virus expressing a NS1A protein in which amino acids 123/124
or 126/127 are mutated. We conclude that binding of PKR to the
123–127 sequence of the NS1A protein is necessary and
sufficient for the inhibition of PKR activation in influenza A
virus-infected cells. We did not find any evidence that a host cell
factor, such as p58IPK (Melville et al., 1999), protects PKR from
activation in cells infected by these two influenza A mutant
viruses. It is therefore likely that inhibition of PKR activation in
influenza A virus-infected cells is mediated solely by the viral
NS1A protein. The binding of the NS1A protein to PKR,
specifically to its N-terminal 230 amino acid region (Li et al.,
2006a), would be expected to prevent PKR from undergoing the
conformational change that is required for its activation (Li et
al., 2006b). In addition, it is possible that the NS1A protein
imports the bound PKR to the nucleus, thereby sequestering it
from its eIF2-α substrate, as has recently been reported for the
TRS1 protein of human cytomegalovirus (Hakki et al., 2006).Other viruses employ different strategies to inhibit the
antiviral action of PKR. For example, the ICP34.5 protein of
herpes simplex-1 binds to a specific cellular protein phospha-
tase, thereby promoting its ability to dephosphorylate eIF2-α
(Leib et al., 2000). Other viruses encode proteins that serve as
pseudo substrates for activated PKR, and thus spare eIF2-α
from phosphorylation (Davies et al., 1993). Some viruses target
the activation of PKR by dsRNA by several mechanisms. For
example, adenovirus encodes a small RNA, VAI RNA, which
binds to the dsRNA-binding domain of PKR without activating
it, thereby blocking activation by dsRNA (Mathews and Shenk,
1991). Several viruses encode RNA-binding proteins that
sequester dsRNA away from PKR (Chang et al., 1992; Imani
and Jacobs, 1988). In contrast, the RNA-binding domain of the
NS1A protein of influenza A virus, which has a low affinity for
dsRNA (Chien et al., 2004), is not able to sequester dsRNA
away from PKR in infected cells (Li et al., 2006b; Min and
Krug, 2006).
Our results also reveal that the NS1A protein mediates
temporal control of viral RNA synthesis in influenza A virus-
infected cells. Gene expression in influenza A virus-infected
Fig. 5. PKR activation and deregulation of the time course of viral RNA synthesis are not coupled. (A) The time course of viral protein synthesis in mouse PKR+/+ and
PKR−/− cells after infection with either wt virus or 123/124 virus at a multiplicity of infection of 5 pfu/cell. (B) The amounts of the M1 and NP mRNAs at 2 h after
infection of PKR−/− cells with the 123/124 virus relative to the amounts of these two mRNAs at 2 h after wt virus infection.
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(Krug et al., 1989; Shapiro et al., 1987; Skehel, 1973). During
the early phase the NS and NP vRNAs are selectively replicated
and transcribed, whereas during the late phase all vRNAs,
including the NS and NP vRNAs, are replicated and transcribed
at a high rate. The mechanism of this temporal regulation of
influenza virus RNA synthesis has remained a mystery for
approximately 20 years (Krug et al., 1989; Shapiro et al., 1987).
Our results provide the first insight into this mechanism by
demonstrating that amino acid changes at a specific position in
the NS1A protein (amino acids 123 and 124) result in the
deregulation of the time course of viral RNA synthesis: both
early and late vRNAs, viral mRNAs and proteins are
synthesized at high levels at very early times after infection.
Deregulation also occurs in mouse PKR−/− cells, demonstrat-
ing that this phenotype is independent of PKR activation. The
most likely interpretation of our results is that the NS1A protein,
via a site that includes amino acids 123 and 124, functionally
interacts with the viral polymerase to mediate temporal
regulation of viral RNA synthesis during virus infection. This
conclusion is consistent with previous studies that suggested a
role for the NS1A protein in viral RNA synthesis (Falcon et al.,
2004; Marion et al., 1997; Scholtissek and Spring, 1982;
Shimizu et al., 1994). Although our genetic experiments show
that there is a functional interaction between the NS1A protein
and the viral polymerase, other experimental approaches are
needed to elucidate the mode of this interaction. For example,
does the NS1A-polymerase functional interaction involve directbinding of the NS1A protein to the viral polymerase? Does the
NS1A protein suppress vRNA and/or viral mRNA synthesis at
early times or enhance synthesis at late times? Is this functional
interaction responsible for the selective replication and
transcription of the NS and NP vRNAs at early times after
infection?
As shown here, amino acids 123 and 124 of the NS1A
protein mediate two different functions in influenza A virus-
infected cells: binding of PKR that results in inhibition of its
activation; and functional interaction with the viral polymerase
that results in deregulation of the time course of viral RNA
synthesis. It is therefore not surprising that the amino acids at
these two positions (I123 and M124) in the NS1A protein,
which are at the surface of the protein in a loop between two β-
sheets (Bornholdt and Prasad, 2006), are highly conserved
(approximately 95%) in human influenza A viruses (Macken et
al., 2001). PKR binding and functional interaction with the
polymerase would not be expected to compete for this site on
the NS1A protein because these two interactions most likely
occur at two different locations in the cell. PKR is located in the
cytoplasm (Vattem et al., 2001; Wu et al., 1998; Zhu et al.,
1997), where it would be expected to bind to NS1A proteins
prior to their import into the nucleus. In contrast, the viral RNA
polymerase that carries out viral RNA synthesis is located in the
nucleus (Krug et al., 1989), where it would be expected to
interact with NS1A proteins, which are also predominately
localized in the nucleus (Greenspan et al., 1988; Min and Krug,
2006). Our identification of two new functional interactions of
242 J.-Y. Min et al. / Virology 363 (2007) 236–243the NS1A protein highlights the participation of the highly
expressed NS1A protein in multiple functions in influenza A
virus-infected cells.
Materials and methods
In vitro PKR assays
To generate C-terminal truncated NS1A proteins, PCR
mutagenesis was used to introduce stop codons at the indicated
positions in DNA encoding the NS1A protein. PCR mutagen-
esis was also used to substitute alanines (or in one case, a
threonine) for the indicated wild-type amino acids in the NS1A
protein. Mutated and wild-type DNA were inserted into the
unique BamH1 and EcoRI sites of the pGEX-3X plasmid, and
GST-NS1A proteins were produced in BL21 E. coli and
purified by glutathione Sepharose chromatography (Nemeroff
et al., 1995). To assay binding of NS1A proteins to PKR in
vitro, equimolar amounts of the indicated GST-NS1A protein
was mixed with a cell extract containing FLAG-tagged PKR,
followed by glutathione Sepharose chromatography and
immunoblots using FLAG monoclonal antibody (Li et al.,
2006a). For the in vitro PKR activation assays, V5-tagged PKR
expressed in 293T cells was immunoprecipitated with anti-V5
monoclonal antibody (Li et al., 2006a). The immobilized PKR
(∼15 nM) was first incubated with the indicated GST-NS1A
protein (270 nM) for 5 min at 4 °C, followed by the addition of
the PKR activator (purified PACT domain 3, 10 nM) and
(γ-32P) ATP. After incubation for 30 min at 30 °C, the amount
of 32P-labeled PKR was determined by SDS-polyacrylamide
gel electrophoresis and autoradiography.
Cells and viruses
The procedures for plaque assays in MDCK cells and for
growth of influenza A/Udorn/72 virus in MDCK and A549 cells
have been described (Min and Krug, 2006). Recombinant
Udorn influenza viruses expressing mutant NS1A proteins were
generated using the 12-plasmid transfection procedure (Min and
Krug, 2006; Noah et al., 2003; Takeda et al., 2002). The pHH21
plasmid encoding NS genomic RNA contained the indicated
mutations in the NS1A reading frame generated by PCR
mutagenesis. All eight genome RNA segments of recombinant
viruses were sequenced to verify that the only mutation in the
recombinant viruses was the introduced NS mutation. Mouse
PKR+/+ and PKR−/− cells were kindly provided by Bryan
Williams, and were infected with influenza A/Udorn/72 virus
under the same conditions used for A549 cells.
Measurement of influenza viral mRNAs and vRNAs by
real-time quantitative RT-PCR
RNA was isolated from infected cells by using the Trizol
reagent at the indicated times after infection of A549 cells. For
each sample, 1 μg of total RNA, which corresponds to equal cell
equivalents, was reverse transcribed using either an oligo(dT)
primer (for viral mRNAs) or a primer specific for the common3′ ends of influenza vRNAs. The amounts of particular viral
mRNAs and vRNAs were determined using the TaqMan Gene
Expression Assay (Applied Biosystems) with 5′ and 3′ primers
specific for the particular viral mRNA or vRNA and a 6-
carboxyfluorescein dye-labeled TaqMan MGB (minor groove
binder) internal probe (Twu et al., 2006). Real-time PCR
analysis was carried out using the Perkin-Elmer/Applied
Biosystems 7900HT sequence detector.
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